Russell Scott - Concepedia

Author

Russell Scott

Also Known As

B S Scott, C. Swenson Brousell, Josse, Robert, Kingsley Nirmalaraj, Michael Stepanavage, Philip J. Barter, R S SCOTT, R S Scott, R SCOTT, R Scott

370

Publications

19.7K

Citations

H-Index

214

Concepts

All Affiliations

Christchurch Hospital Canterbury Health Laboratories Baylor University The University of Sydney Princess Margaret Hospital

About

Russell Scott is an author at Christchurch Hospital specializing in medicine, urology, and diabetes.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	33	78	10.4K
2	Health Sciences	18	22	1K
3	Natural Sciences	2	2	202
4	Business	1	1	33
5	Engineering	1	1	21

Russell Scott

147

Publications

15K

Citations

H-Index

Page 1

	Year	Citations
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial A Keech, R. John Simes, Philip J. Barter, The Lancet Diabetes ManagementCardiovascular DiseaseHealth PolicyLong-term Fenofibrate TherapyDiabetes	2005	3.2K
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais, The Lancet Metabolic SyndromeDiabetes ManagementCardiovascular DiseaseHealth PolicyCardiovascular Outcomes	2019	2.8K
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial Frederick J. Raal, Evan A. Stein, Robert Dufour, The Lancet Metabolic SyndromeLipid DisorderHeterozygous Familial HypercholesterolaemiaOxysterolMedicine	2014	734
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais, The Lancet Metabolic SyndromeDiabetes ManagementUrologyChronic Kidney DiseaseDiabetes	2019	600
Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome Russell Scott, Richard O’Brien, Greg Fulcher, Diabetes Care	2008	545
Efficacy and Safety of Statin Therapy in Children With Familial Hypercholesterolemia Saskia de Jongh, Leiv Ose, Tamás Szamosi, Circulation	2002	308
Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes Russell Scott, Mei Wu, Miguel A. Sánchez, International Journal of Clinical Practice	2006	259
Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency Juliana C.N. Chan, Russell Scott, Juan Camilo Arjona Ferreira, Diabetes Obesity and Metabolism	2008	238
Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes* Russell Scott, Tom Loeys, Melanie J. Davies, Diabetes Obesity and Metabolism	2008	222
Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes Gary Meininger, Russell Scott, Maria Alba, Diabetes Care	2011	211

Page 1